Health Related quality of life in patients with rheumatoid arthritis during the first year of treatment by TNF inhibitors (assessed by SF-36 questionnaire and compared with a sample of general Czech population) – results from the Czech biologics registry ATTRA

Czech version

Authors: J. Závada ¹; M. Uher ²; K. Hejduk ²; J. Vencovský ^3,1; K. Pavelka ^1,3; Kolektiv Lékařů Biologických Center
Authors‘ workplace: Revmatologický ústav, Praha ¹; Institut biostatistiky a analýz, Masarykova univerzita, Brno ²; Česká revmatologická společnost JEP ³
Published in: Čes. Revmatol., 21, 2013, No. 3, p. 123-130.
Category: Original Papers

Overview

Introduction:
Health-related quality of life (HRQOL) is an important indicator of severity of musculoskeletal conditions. SF-36 is a generic patient-reported measure of HRQOL implemented in the follow-up protocol of the ATTRA registry. Our goal was to assess HRQOL (as measured by SF-36 and its individual domains) before and after first-line treatment with TNF inhibitors (Etanercept, Adalimumab, Infliximab) in patients with rheumatoid arthritis, and to compare the results with age-adjusted normative values of general Czech population.

Patients and methods:
823 RA patients with available clinical data (DAS28, HAQ), and HRQOL data (SF-36) completing one year tratment were included in the analysis.

Results:
In the analyzed sample there were 82 % females and 18 % males with median age of 51 years (IQR 41-58) and median disease duration of 7 years (IQR 3-13) at the beginning of anti-TNF therapy. 28 % were treated by infliximab, 46 % by adalimumab, and 26 % by etanercept. Clinically meaningful and statistically significant improvements were observed in all dimensions of HRQOL assessed by SF-36, and in the mental health domain the RA patients reached similar scores as individuals from the age-standardized sample of general Czech population.

Conclusions:
RA had a severe impact on all dimensions of HRQOL. During one year of treatment, TNF-inhibitors substantially improved HRQOL, though not to the normal level.

Key words:
Health-related quality of life, SF-36, biologic disease-modifying anti-rheumatic drugs, anti-tumour necrosis factor drugs, rheumatoid arthritis, registry

Sources

1. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.

2. SokkaT, Kautiainen H, Hannonen P, Pincus T. Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum 2006;54:3113-8.

3: Bellamy N, Boers M, Felson D, Fries J, Furst D, Henry D, Liang M, Lovell D, March L, Strand V, et al. Health status instruments / utilities. J Rheumatol 1995;22:1203-7.

4. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83.

5. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247-63.

6. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.

7. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43:1478-87.

8. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.

9. Sobotík Z. Zkušenosti s použitím předběžné české verze amerického dotazníku o zdraví (SF36). Zdravotnictví v ČR 1998;1-2:50-54.

10. Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd ed. Mahwah NJ. Lawrence Erlbaum; 1988.

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

Recommendations of the Czech Society for Rheumatology for the treatment of patients with SLE

What are the predictive factors of response to treatment with tocilizumab in routine clinical practice? The experience of the Czech national registry ATTRA

Myocophenolate mofetil in the treatment of systemic lupus erythematosus

Article was published in

Czech Rheumatology

2013 Issue 3